Press Release Archives - Page 14 of 22

Spectral Medical Announces Appointment of Leading Industry Executive Sam Amory as Dialco President

Previously launched start-up division for a major medical device company that grew to the number two position in the U.S. market TORONTO, Canada –May 16, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing...

Spectral to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th

TORONTO, Canada –May 13, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral to Present at Investor Summit Group’s Q2 In-Person Conference on May 3rd in NYC

TORONTO, Canada –April 27, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Announces Appointment of Blair McInnis as CFO

TORONTO, Canada – March 21, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Dialco Medical Announces Formation of Medical Advisory Board to Support the Continued Development of DIMI Device.

TORONTO, Canada – March 16, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”) has formed a Medical Advisory Board to support in guiding the DIMI usability trial and...

Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022

TORONTO, Canada – March 4, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.